{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:17:58Z","timestamp":1790720278820,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2004,5,18]],"date-time":"2004-05-18T00:00:00Z","timestamp":1084838400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1038\/sj.bjc.6601811","type":"journal-article","created":{"date-parts":[[2004,5,18]],"date-time":"2004-05-18T17:16:45Z","timestamp":1084900605000},"page":"2261-2267","source":"Crossref","is-referenced-by-count":48,"title":["A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours"],"prefix":"10.1038","volume":"90","author":[{"given":"F M","family":"Wachters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H J M","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J G","family":"Maring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Gietema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Porro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Dumez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E G E","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A T","family":"van Oosterom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,5,18]]},"reference":[{"key":"BF6601811_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s002800050547","volume":"39","author":"AE Ahmed","year":"1996","unstructured":"Ahmed AE, Jacob S, Giovanella BC, Kozielski AJ, Stehlin Jr JS, Liehr JG (1996) Influence of route of administration on [3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies. Cancer Chemother Pharmacol 39: 122\u2013130","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6601811_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0168-3659(99)00243-6","volume":"65","author":"VR Caiolfa","year":"2000","unstructured":"Caiolfa VR, Zamai M, Fiorino A, Frigerio E, Pellizzoni C, D'Argy R, Ghiglieri A, Castelli MG, Farao M, Pesenti E, Gigli M, Angelucci F, Suarato A (2000) Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J Control Release 65: 105\u2013119","journal-title":"J Control Release"},{"key":"BF6601811_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31\u201341","journal-title":"Nephron"},{"key":"BF6601811_CR4","first-page":"198","volume":"19","author":"JS De Bono","year":"2000","unstructured":"De Bono JS, Bissett D, Twelves C, Main M, Muirhead F, Robson L, Fraier D, Magne MI, Porro M, Speed W, Cassidy J (2000) Phase I pharmacokinetic (PK) study of MAG-CPT (PNU 166148), a polymeric derivative of camptothecin (CPT). Proc Am Soc Clin Oncol 19: 198","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6601811_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0014-4827(91)90534-2","volume":"193","author":"G Del Bino","year":"1991","unstructured":"Del Bino G, Lassota P, Darzynkiewicz Z (1991) The S-phase cytotoxicity of camptothecin. Exp Cell Res 193: 27\u201335","journal-title":"Exp Cell Res"},{"key":"BF6601811_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1461-5347(99)00211-4","volume":"2","author":"R Duncan","year":"1999","unstructured":"Duncan R (1999) Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Technol Today 2: 441\u2013449","journal-title":"Pharm Sci Technol Today"},{"key":"BF6601811_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0731-7085(99)00315-5","volume":"22","author":"D Fraier","year":"2000","unstructured":"Fraier D, Frigerio E, Brianceschi G, Casati M, Benecchi A, James C (2000) Determination of MAG-camptothecin, a new polymer-bound camptothecin derivative, and free camptothecin in dog plasma by HPLC with fluorimetric detection. J Pharm Biomed Anal 22: 505\u2013514","journal-title":"J Pharm Biomed Anal"},{"key":"BF6601811_CR8","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1021\/jm00085a012","volume":"35","author":"EJ Franssen","year":"1992","unstructured":"Franssen EJ, Koiter J, Kuipers CA, Bruins AP, Moolenaar F, de Zeeuw D, Kruizinga WH, Kellogg RM, Meijer DK (1992) Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug\u2013protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. J Med Chem 35: 1246\u20131259","journal-title":"J Med Chem"},{"key":"BF6601811_CR9","first-page":"461","volume":"54","author":"JA Gottlieb","year":"1970","unstructured":"Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461\u2013470","journal-title":"Cancer Chemother Rep"},{"key":"BF6601811_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003088-199631020-00001","volume":"31","author":"VM Herben","year":"1996","unstructured":"Herben VM, Bokkel Huinink WW, Beijnen JH (1996) Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31: 85\u2013102","journal-title":"Clin Pharmacokinet"},{"key":"BF6601811_CR11","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1021\/bi00437a018","volume":"28","author":"RP Hertzberg","year":"1989","unstructured":"Hertzberg RP, Caranfa MJ, Hecht SM (1989) On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme\u2013DNA complex. Biochemistry 28: 4629\u20134638","journal-title":"Biochemistry"},{"key":"BF6601811_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/BF02976620","volume":"25","author":"CK Kim","year":"2002","unstructured":"Kim CK, Lim SJ (2002) Recent progress in drug delivery systems for anticancer agents. Arch Pharm Res 25: 229\u2013239","journal-title":"Arch Pharm Res"},{"key":"BF6601811_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1021\/jm00105a017","volume":"34","author":"WD Kingsbury","year":"1991","unstructured":"Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK (1991) Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98\u2013107","journal-title":"J Med Chem"},{"key":"BF6601811_CR14","first-page":"193","volume":"6","author":"H Maeda","year":"1989","unstructured":"Maeda H, Matsumura Y (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6: 193\u2013210","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"BF6601811_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271\u2013284","journal-title":"J Control Release"},{"key":"BF6601811_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/00001813-200104000-00003","volume":"12","author":"JM Meerum Terwogt","year":"2001","unstructured":"Meerum Terwogt JM, Ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH (2001) Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12: 315\u2013323","journal-title":"Anticancer Drugs"},{"key":"BF6601811_CR17","first-page":"7","volume":"5","author":"FM Muggia","year":"1999","unstructured":"Muggia FM (1999) Doxorubicin\u2013polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res 5: 7\u20138","journal-title":"Clin Cancer Res"},{"key":"BF6601811_CR18","first-page":"515","volume":"56","author":"FM Muggia","year":"1972","unstructured":"Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515\u2013521","journal-title":"Cancer Chemother Rep"},{"key":"BF6601811_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00280-003-0685-x","volume":"52","author":"N Sarapa","year":"2003","unstructured":"Sarapa N, Britto MR, Speed W, Jannuzzo M, Breda M, James CA, Porro M, Rocchetti M, Wanders A, Mahteme H, Nygren P (2003) Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother Pharmacol 52: 424\u2013430","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6601811_CR20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/sj.bjc.6600516","volume":"87","author":"NE Schoemaker","year":"2002","unstructured":"Schoemaker NE, Van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Porro M, Beijnen JH, Schellens JH, Ten Bokkel Huinink WW (2002) A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer 87: 608\u2013614","journal-title":"Br J Cancer"},{"key":"BF6601811_CR21","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2002.20.6.1668","volume":"20","author":"LW Seymour","year":"2002","unstructured":"Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ (2002) Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20: 1668\u20131676","journal-title":"J Clin Oncol"},{"key":"BF6601811_CR22","first-page":"2747","volume":"4","author":"A Sparreboom","year":"1998","unstructured":"Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, Verweij J (1998) Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 4: 2747\u20132754","journal-title":"Clin Cancer Res"},{"key":"BF6601811_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"BF6601811_CR24","first-page":"83","volume":"5","author":"PA Vasey","year":"1999","unstructured":"Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents\u2013drug\u2013polymer conjugates. Cancer Research Campaign Phase I\/II Committee. Clin Cancer Res 5: 83\u201394","journal-title":"Clin Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6601811.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601811","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601811.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:07:26Z","timestamp":1684411646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6601811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,18]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["BF6601811"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6601811","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,18]]}}}